The federal government plans to propose a rule in December that would end the option allowing television and radio drug ads to send viewers to a website, phone number, or other source for a medication's full risk information instead of including it in the ad itself.
Nothing has changed yet. The plan appears on the administration's regulatory agenda as a future proposed rule. It is not in effect, it is not final, and the FDA says it is not a ban. If the proposal is published as scheduled, a public comment period will follow, and any final rule would come later.
The issue matters to viewers because prescription drug ads are a constant presence on American television, and the quick list of risks at the end of many ads reflects the regulation now under review.
The Provision Under Review
Federal rules require broadcast drug ads to include a spoken "major statement" of a medication's most important risks. Ads must also include a "summary" of risk information, unless they make "adequate provision" for viewers to get the drug's full FDA-approved prescribing information from another source.
That option is part of the regulation at 21 C.F.R. 202.1(e). The FDA's drug advertising glossary explains that the brief summary would take many minutes to read aloud or scroll across a TV screen. As a result, broadcast ads may include only the most important risks if they tell viewers how to find the full prescribing information. Accepted sources include a health care provider, a toll-free phone number, a current magazine that carries a print ad, and a website.
The planned rule would change that. The federal agenda entry for the rule, titled "Transparency in Direct-to-Consumer Advertising," says HHS and the FDA intend to issue a proposed rule in December 2026. The rule would eliminate the option for radio and television drug ads to meet the summary requirement by pointing to safety information in another source.
The agenda entry offers a summary rather than draft text. The FDA says the change would require broadcast ads to disclose all relevant risk and safety information within the ad itself. The agency expects the rule to be economically significant, with annual costs exceeding $100 million for at least one year. It says companies may need to buy more airtime, devote more of existing airtime to safety information, or stop advertising if the added cost is too high.
According to the Mintz FDA regulatory newsletter, the rulemaking could either delete the adequate provision language entirely or substantially modify it. The newsletter also notes that the administration signaled its intent to revoke the provision in September 2025, so its appearance on the agenda was expected. The agenda entry cites a Sept. 9, 2025, presidential memorandum directing HHS and the FDA to increase risk information in drug advertising.
What Viewers Could See
Two outcomes seem possible, and it is not yet clear which will happen.
One is longer ads with more spoken risk information. The other is fewer broadcast drug ads, because including a complete summary could make commercials far more expensive. The FDA says the rule would not ban drug advertising. Some regulatory lawyers disagree about the practical effect. Attorneys writing on the FDA Law Blog said the change could effectively ban broadcast drug ads by making them too costly. Those are assessments of a proposal whose text has not yet been published.
An important question remains unanswered. The agenda entry refers to broadcast media such as radio and television, but its statement of need also mentions the growth of drug advertising on digital platforms. It does not say whether the new requirement would apply to social media or streaming ads.
The proposal would not change a drug's approval, label, availability, or price. It concerns how risk information appears in advertising. Patients who take an advertised drug would still receive the same prescribing information from their pharmacy.
Who Has the Most at Stake
Drug companies and broadcasters face the most direct financial effect, given the added airtime costs the FDA itself anticipates.
Patients and caregivers are affected in a different way. Many people first learn about a treatment from an ad and then ask a clinician about it. More on-air risk information could make those conversations better informed. Fewer ads could mean some people never hear about an option that might suit them, an argument supporters of current advertising practices have made.
Legal challenges are possible. Mintz notes that the public record from the rulemaking would become important if constitutional or legal challenges are filed against a final rule. The proposal would also add to existing rules. A 2023 FDA final rule already requires the major statement in TV and radio ads to be presented in a clear, conspicuous, and neutral manner.
Steps That Do Not Depend on the Outcome
No one needs to act on a planned proposal. But the underlying issue, that a short broadcast ad cannot convey a drug's full risk picture, is worth addressing directly.
Anyone considering a medication seen in an ad can ask a clinician or pharmacist three questions: What are the most serious risks? Would a generic or older drug with a longer safety record work as well? What would the out-of-pocket cost be? Full FDA-approved prescribing information is available free through the FDA's Drugs@FDA database and from pharmacists on request.
An ad is marketing, not medical advice. Nobody should start, stop, or switch a prescription based on a commercial.
The next milestone is publication. If the proposed rule appears in December as planned, the public will be able to submit comments through the federal docket. Law firm Latham & Watkins said such comment periods typically run 60 to 90 days. Regulatory agendas are estimates, and dates often slip. MedicalDaily will report the proposal's actual text when it is published, including whether it reaches digital advertising.
Key Questions Answered
What is being proposed? A rule that would end the option for TV and radio prescription drug ads to meet the summary requirement by directing viewers to an outside source for full risk information.
Is this in effect now? No. It is listed on the federal regulatory agenda as a proposed rule planned for December 2026. A comment period and a separate final rule would follow.
What is the adequate provision option? A regulatory option that lets broadcast ads include only the most important risks if they tell viewers how to get the full prescribing information, such as through a website or toll-free number.
Would drug ads disappear? Unclear. The FDA says the rule is not a ban, but some regulatory lawyers say the added cost could effectively end many broadcast drug ads.
Does it cover social media ads? The agenda entry does not say. That is one of the biggest open questions.
Does anything change about my medication? No. Approvals, labels, availability, and prices are unaffected. The proposal concerns advertising only.
Where can I find a drug's full risks? The FDA-approved prescribing information is available free through Drugs@FDA and from any pharmacist.
